Illumina's 18-month NovaSeq X upgrades boost throughput ~40% and target Q70 accuracy

Headline: Illumina maps 18-month upgrade cadence to boost NovaSeq X capacity and accuracy

NovaSeq X upgrade plan targets higher throughput and Q70 accuracy

Illumina unveils an 18-month roadmap of software, chemistry and consumable upgrades for its NovaSeq X high-throughput sequencer, saying the package will raise per-run output by about 40% to as much as 35 billion reads and deliver Q70-level base-call quality for the first time. The company says the enhancements, which include faster chemistry and new flow-cell architectures, also increase instrument speed by roughly 30% and introduce staggered starts and flexible workflow modes to improve sample-to-answer times.

The updates roll out across the company’s installed base of 8,901 NovaSeq X systems worldwide in the coming weeks, with Illumina framing the campaign as a way to compound value for customers through higher per-run yields, shorter run times and broader protocol compatibility. By pushing base-call accuracy toward Q70, Illumina expects labs to run ultrassensitive assays and detect lower-frequency variants that are important in oncology, rare-disease research and other precision-medicine applications.

Illumina says the 18-month cadence is designed to let labs layer software, chemistry and consumable changes sequentially so improvements multiply over time, enabling deeper whole-genome sequencing or greater sample multiplexing on a single instrument. The company highlights operational benefits such as lower per-sample cost, improved utilization through staggered run starts and reduced idle time from new flow-cell designs, positioning NovaSeq X to support large-scale research, clinical and population sequencing programs.

Deployment logistics and laboratory impact

Illumina plans a global deployment across nearly 9,000 instruments, stressing that upgrades are backward-compatible with the installed base and intended to increase daily sequencing productivity without requiring instrument replacement. The staggered-start option and alternative workflow modes aim to help high-throughput labs match capacity to variable sample arrival and shorten turnaround for time-sensitive assays.

Implications for precision medicine and large-scale studies

By increasing per-run yield and moving toward Q70 accuracy, Illumina expects customers to expand large-cohort studies and ultradeep sequencing protocols on NovaSeq X, improving sensitivity for low-frequency variant detection and supporting broader adoption in clinical and population-scale sequencing initiatives.